Puerto Rico’s pharma industry contributes significantly to the economy and reduces unemployment
InvestPR 22 [InvestPR; February 2022; "Benchmarking Puerto Rico’s Pharma Sector"; https://www.investpr.org/wp-content/uploads/2022/02/Benchmarking-PuertoRicos-Pharma-Sector-PIA-InvestPR.pdf; Accessed 7-16-2023; AW]
For over sixty years Puerto Rico has stood as a global leader in biopharmaceutical manufacturing. The Island is home to 10 of the world’s 20 top-grossing pharmaceutical companies, producing top-selling brands such as Humalog, Humira, Eliquis, Opdivo, Enbrel, Neulasta, Remicade, and Xarelto. In 2019, sector exports totaled more than $44 billion. Of that, $30.89 billion was exported to the U.S. market, while $13.2 billion went to more than 130 countries, significantly more than any U.S. state. Pharma represents 30% of the Island’s GDP, 30% of all manufacturing jobs, and employs over 78,000 people.